



No: 333/CPC1 - PC

Disclosure: On the approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party - Imexpharm Pharmaceutical Joint Stock Company.

Hanoi, 13 February 2026

To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.

Company: CENTRAL PHARMACEUTICAL CPC1.JSC

Stock code: DP1

Head office: No. 87 Nguyen Van Troi Street, Phuong Liet Ward, Hanoi

Phone: 0243. 8643306 Fax: 0243. 8641366

Type of Information Disclosure:

☒ Unusual 24h ☐ Upon Request ☐ Periodic ☐ Other

Content of Report and Information Disclosure:

Central Pharmaceutical CPC1.JSC hereby discloses Resolution of the Board of Directors No. 08/NQ-HĐQT dated 13 February 2026 on the approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party - Imexpharm Pharmaceutical Joint Stock Company.

This information was published on the Company's website on 13 February 2026 at the following link: www.cpc1.com.vn – Shareholders – Information Disclosure.

Our company commits that the reported and disclosed information above is truthful, and we take full legal responsibility for the content of the reported and disclosed information.

Sincerely,

Recipients:

- As stated above;
- Chairwoman of the BOD (for report);
- Board of Management;
- Related units;
- Archives: Clerical, Legal.

**AUTHORIZED PERSON
FOR INFORMATION DISCLOSURE
GENERAL DIRECTOR**



Ta Van Dung

Attachments:

- Resolution No. 08/NQ-HĐQT - CPC1



Hanoi, 13 February 2026

RESOLUTION

On the approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party - Imexpharm Pharmaceutical Joint Stock Company

BOARD OF DIRECTORS**CENTRAL PHARMACEUTICAL CPC1.JSC**

Pursuant to the Law on Enterprises No. 59/2020/QH14 issued on 17 June 2020, as amended and supplemented by Law No. 03/2022/QH15 dated 10 January 2022 and the Law No. 76/2025/QH15 dated 17 June 2025;

Pursuant to the Law on Securities dated 26 November 2019; Law No. 56/2024/QH15 amended 24 November 2024, supplementing a number of provisions of the Law on Securities and other related laws;

Pursuant to the Fifth Amendment of the Charter of Central Pharmaceutical CPC1.JSC dated 11 April 2024;

Pursuant to Submission No. 251/TTr - CPC1 dated 29 January 2026 of the General Director regarding the approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party - Imexpharm Pharmaceutical Joint Stock Company;

Pursuant to the Minutes summarizing the opinions of the Board of Directors No. 07/BBHĐQT - CPC1 dated 13 February 2026.

RESOLVES:

Article 1. Approval of the policy to enter into a contract between Central Pharmaceutical CPC1.JSC and the related party - Imexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as Imexpharm), as proposed in Submission No. 251/TTr- CPC1 dated 29 January 2026 of the General Director.

Article 2. Authorization for the Director of Central Pharmaceutical CPC1.JSC - Ho Chi Minh Branch to decide on the contents and detailed terms, organize the negotiation, execution, and implementation of the contract in accordance with the Company's regulations and the provisions of applicable law, ensuring the lawful rights and interests of the Company.

Article 3: This Resolution shall take effect from the date of signing.

Members of the Board of Directors, the Board of Management, Director of Central Pharmaceutical CPC1.JSC- Ho Chi Minh Branch, the Company's departments, and relevant parties shall be responsible for implementing this Resolution in accordance with the Company's Charter and the provisions of law.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN**

Recipients:

- As stated in Article 3;
- Audit Committee;
- Archives: Clerical, Secretary.



Han Thi Khanh Vinh